Synovetin OA is an intra-articular treatment that leverages the unique radioisotope tin-117m to address inflammation within the joint. Synovetin OA is the only treatment designed to directly target synovial inflammation, the driver of pain and joint damage, and help prevent further joint damage, especially when used earlier in the disease.4-6
What is Synovetin OA®?
Synovetin OA is a first-line choice best used in early OA management to relieve the pain and help preserve the health of the joint.

Up to 1 full year of relief with just 1 simple, safe treatment
Compared with other canine OA treatments that require daily or monthly dosing, Synovetin OA is a convenient option that also eliminates compliance problems.

Peer reviewed, published data prove up to 1 year of relief with just 1 treatment4
Synovetin OA provides increasing pain relief and improved mobility over a year, yet with no active tin-117m remaining in the joint.

*Overall treatment success based on a composite of force plate, Canine Brief Pain Index (CBPI), and clinician assessments for the label dose.

Exceptionally safe with no systemic side effects— so you can treat with confidence7
Tin-117m, the active ingredient in Synovetin OA, has been shown to slow OA progression in rodent models

Learn More: See the poster presented the Society of Nuclear Medicine and Molecular Imaging Annual Conference.








In the joint fluid of an arthritic joint, inflammatory cells drive pain and progression of the disease. Inflammation is the source of pain–where it begins. The inflammatory cells in inflamed joints produce substances that cause even more inflammation and damage to the joint. This is called “the vicious cycle of inflammation” and if left untreated, it causes ongoing inflammation, pain, and damage to the cartilage that lines the joint.
The effectiveness of Synovetin OA was studied in multiple clinical trials of dogs with elbow arthritis. Researchers evaluated Synovetin OA in its ability to relieve arthritis pain in dogs, such as lameness (limping), level of activity, and signs of pain during the year-long studies.
In most cases, you should begin to see improvement in your dog’s mobility within a few weeks, depending on the severity of arthritis. Some dog owners see results almost immediately, while in other instances of severe arthritis, it can be up to 2 months. This improvement should continue over time as Synovetin OA works inside the joint to address the inflammation.
Synovetin OA is a treatment that consists of microscopic particles of the unique isotope tin-117m. These targeted particles emit a form of mild radiation energy that inactivates the harmful cells causing inflammation within the joint and the tissues surrounding the joint (called the synovium) and that drive the loss of cartilage. This activity helps to restore joint health and provides very long lasting pain relief without the systemic side effects that can commonly occur with daily and monthly dog arthritis drugs.
Synovetin OA is administered directly into the arthritic joint where it remains and works locally to eliminate inflammation–the driver of pain and progression of arthritis. It does not travel through the dog’s body and therefore causes no systemic side effects. This is in contrast to pain drugs such as daily NSAIDs or monthly injections, which are metabolized systemically in the dog’s body and have known, can have significant side effects.






